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EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis 1 
and inflammation 2 
 3 
Jaclyn S. Pearson1*, Cristina Giogha1*, Sabrina Mühlen1∞, Ueli Nachbur2,3, Chi L. L. Pham4, Ying 4 
Zhang1, Joanne M. Hildebrand2,3, Clare V. Oates1, Tania Wong Fok Lung1, Danielle Ingle1, Laura 5 
F. Dagley2,3, Aleksandra Bankovacki2,3, Emma J. Petrie2,3, Gunnar N. Schroeder5^, Valerie F. 6 
Crepin5, Gad Frankel5, Seth L. Masters2,3, James Vince2,3, James M. Murphy2,3, Margaret Sunde4, 7 
Andrew I. Webb2,3, John Silke2,3 and Elizabeth L. Hartland1# 8 
*equal contribution 9 
 10 
1Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty 11 
Institute for Infection and Immunity, Melbourne 3000, Australia  12 
2The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Melbourne, 13 
Australia  14 
3Department of Medical Biology, University of Melbourne, Victoria 3010, Australia 15 
4Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales 16 
2006, Australia 17 
5MRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Imperial 18 
College London, SW7 2AZ, UK  19 
 20 
∞ Current address: Department of Molecular Infection Biology, Helmholtz-Centre for Infection 21 
Research, 38124 Braunschweig, Germany 22 
^ Current address: Centre for Experimental Medicine, Queen's University Belfast, BT9 7BL, UK 23 
 24 
#Correspondence: hartland@unimelb.edu.au 25 
 26 
Manuscript information:  27 
Word count: 1420 28 
Running title: Type III effector EspL blocks necroptosis  29 
Keywords: EPEC/necroptosis/RHIM/cysteine protease 30 
  31 
 2
Cell death signalling pathways contribute to tissue homeostasis and provide innate protection 32 
from infection. Adaptor proteins such as RIPK1, RIPK3, TRIF and ZBP1/DAI that contain 33 
receptor-interacting protein (RIP) homotypic interaction motifs (RHIM) play a key role in 34 
cell death and inflammatory signalling 1-3. RHIM-dependent interactions help drive a caspase-35 
independent form of cell death termed necroptosis 4,5. Here we report that the bacterial 36 
pathogen enteropathogenic Escherichia coli (EPEC) uses the type III secretion system (T3SS) 37 
effector EspL to degrade the RHIM containing proteins, RIPK1, RIPK3, TRIF and 38 
ZBP1/DAI during infection. This required a previously unrecognised tripartite cysteine 39 
protease motif in EspL (Cys47, His131, Asp153) that cleaved within the RHIM of these proteins. 40 
Bacterial infection and/or ectopic expression of EspL led to rapid inactivation of RIPK1, 41 
RIPK3, TRIF and ZBP1/DAI and inhibition of TNF, LPS or poly(I:C)-induced necroptosis 42 
and inflammatory signalling. Furthermore, EPEC infection inhibited TNF-induced 43 
phosphorylation and plasma membrane localization of MLKL. In vivo, EspL cysteine 44 
protease activity contributed to persistent colonization of mice by the EPEC-like mouse 45 
pathogen Citrobacter rodentium. The activity of EspL defines a family of T3SS cysteine 46 
protease effectors found in a range of bacteria and reveals a mechanism by which 47 
gastrointestinal pathogens directly target RHIM-dependent inflammatory and necroptotic 48 
signalling pathways.  49 
 50 
RHIM containing proteins, including RIPK1, RIPK3, TRIF and ZBP1/DAI, play essential roles in 51 
the regulation of inflammatory and cell death-signalling pathways 5. RIPK1 is a key regulator of the 52 
NF-κB signalling pathway in response to TNF/TNFR1 stimulation, and may induce apoptosis 53 
through formation of a cytosolic complex containing TRADD/FADD and caspase-8 6. However, 54 
upon inhibition of caspase-8 activity, RIPK1 binds RIPK3 through RHIM-RHIM interactions 55 
leading to phosphorylation of RIPK3 and the recruitment and phosphorylation of MLKL by 56 
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activated RIPK3 7-11. Phosphorylated oligomeric MLKL translocates to the plasma membrane, 57 
which leads to the caspase independent form of cell death termed necroptosis 12,13. Necroptosis may 58 
also result from TRIF or DAI/ZBP1 interactions with RIPK1 and RIPK3, which are also mediated 59 
by RHIM-RHIM interactions 14,15. In addition, RIPK3 can promote NLRP3 inflammasome 60 
activation independently of necroptosis that is thought to be triggered by RHIM-RHIM amyloid 61 
formation 16. 62 
 63 
Infection of intestinal epithelial cells with the attaching and effacing enteropathogen, EPEC, leads 64 
to rapid inhibition of host inflammatory and apoptosis signalling pathways due to the activity of 65 
T3SS effectors 17. While studying the effect of EPEC infection on assembly of the TNFR1 receptor 66 
complex, we observed that RIPK1 was rapidly degraded during wild type EPEC infection 67 
(E2348/69) but not during infection with the T3SS mutant (ΔescN) (Supplementary Figure 1a).  By 68 
testing derivatives of EPEC lacking the genomic islands PP4 alone (ΔPP4) or PP4 and IE6 69 
(ΔPP4/IE6), we identified IE6 and subsequently the gene encoding the effector EspL as essential 70 
for T3SS-dependent RIPK1 degradation (Fig. 1a; Supplementary Figure 1b). espL is located 71 
upstream of the T3SS effector genes, nleB1 and nleE, which encode known inhibitors of apoptosis 72 
and NF-κB activation respectively (Fig. 1a) 18-20. We confirmed that EspL was translocated by the 73 
T3SS using the TEM1 β-lactamase reporter 21 and that deletion of espL had no impact on actin 74 
accretion by EPEC, a measure of adherence and T3SS activity (Supplementary Figure 1c-e).  75 
 76 
In mammalian cells, RIPK1 may be removed by K48-linked ubiquitylation and proteosomal 77 
degradation or by caspase-mediated cleavage 22-24. However, neither caspase nor proteasome 78 
inhibitors, z-VAD-FMK (z-VAD) and MG132 respectively, prevented EspL-dependent loss of 79 
RIPK1 (Fig. 1b). Therefore, we speculated that EspL might mediate direct degradation of RIPK1. 80 
Although amino acid sequence analysis failed to uncover any canonical protease motifs, alignment 81 
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of EspL with homologues identified by BLAST 25 from a range of bacterial pathogens revealed a 82 
putative conserved cysteine protease motif with the possible catalytic residues Cys47, His131 and 83 
Asp153 (Fig. 1c, d, 2a; Supplementary Figure 2). Despite lacking primary amino acid sequence 84 
similarity with known cysteine proteases, the secondary structure of EspL predicted by Phyre 26 85 
showed N-terminal similarity to the CA clan of papain-like cysteine proteases, which includes the 86 
unrelated T3SS effector YopT from Yersinia spp. (Fig. 1c) 27. Despite this, the broad spectrum 87 
cysteine protease inhibitors, antipain and Z-FA-FMK had no or only weak effect on EspL activity 88 
(Supplementary Figure 1f). Complementation of EPEC strain ΔPP4/IE6 or the ΔespL mutant with 89 
native EspL expressed in trans restored RIPK1 degradation. However, alanine substitution of Cys47, 90 
His131 and Asp153 but not Cys40 abrogated EspL-induced RIPK1 degradation, confirming the crucial 91 
role of these amino acids in EspL activity (Fig. 1d).  92 
 93 
To determine the specificity of EspL for RIPK1 degradation, we examined the effect of EPEC 94 
infection on human as well as murine RIP kinases by immunoblot. In addition to RIPK1, 95 
catalytically active EspL also induced loss of RIPK3, which shares a high degree of similarity with 96 
RIPK1 28 (Fig. 1d, Supplementary Figure 3a). Levels of RIPK2 were unaffected by EspL. Using an 97 
antibody generated to residues 385-650 of RIPK1, we detected a ~14 kDa cleavage product 98 
following ectopic expression of codon optimised Flag-EspL in HEK293T cells, suggesting that 99 
EspL removed the C-terminus of RIPK1 which encompasses the RHIM (Supplementary Figure 3b). 100 
To test the ability of EspL to cleave all mammalian RHIM containing proteins directly, we 101 
incubated purified recombinant EspL with the purified RHIM-containing regions of RIPK1, RIPK3, 102 
TRIF and ZBP1 and observed cleavage by catalytically active EspL for all RHIM proteins (Fig. 2b). 103 
Intact mass spectrometry and N-terminal sequencing of the cleavage products from RIPK3 and 104 
TRIF identified the cleavage site as QxGxx↓N (P5-P4-P3-P2-P1-P1’) (Fig. 2b, c, Supplementary 105 
Figure 3c, d). Substitution of V448, Q449, I450 and G451 with alanine abrogated the ability of EspL to 106 
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cleave RIPK3 during EPEC infection suggesting that this conserved RHIM sequence was important 107 
for substrate recognition by EspL (Supplementary Figure 3e). EspL also possessed the ability to 108 
cleave the viral RHIM containing protein M45 from MCMV (Supplementary Figure 3f). 109 
 110 
Given the observed cleavage of RIPK1 and RIPK3, we hypothesised that EspL would prevent 111 
RIPK1/RIPK3-dependent necroptosis. Mouse dermal fibroblasts (MDF) were used to create stable, 112 
doxycycline inducible cell lines expressing EspL or EspLC47S. Induction of catalytically active EspL 113 
was coincident with loss of RIPK1 and RIPK3 and this effect was reversible upon removal of 114 
induction (Supplementary Figure 4a, b). Cells expressing EspL were protected from necroptotic cell 115 
death, as measured by PI uptake, when induced by treatment with TNF, QVD or z-VAD (as caspase 116 
inhibitors) and the Smac-mimetic IAP antagonist, compound A (Cp.A) as an inhibitor of NF-κB 117 
activation 29. These conditions are known to induce cell death by necroptosis 13. This protection 118 
required EspL activity (Supplementary Figure 4c, 5a, b). EspL expression in MDF cells also 119 
prevented MLKL oligomerization and membrane translocation (Supplementary Figure 5c), two 120 
hallmarks of necroptosis 13. During infection, EPEC blocked MLKL phosphorylation, 121 
oligomerization and membrane translocation and consequently necroptosis in HT-29 cells in an 122 
EspL dependent manner (Fig. 3, Supplementary Figure 6). 123 
 124 
Apart from EspL, the T3SS effector NleB1 from EPEC can block TNF induced necroptosis by 125 
modifying a conserved arginine in the death domain of RIPK1 with N-acetyl glucosamine 126 
(GlcNAc) 19. Consistent with partial redundancy in EspL and NleB1 function, only EPEC 127 
derivatives lacking both espL and nleB1 (ΔPP4/IE6 or ΔespLnleBE) were unable to inhibit TNF-128 
induced necroptosis (Fig. 3b; Supplementary Figure 6). In addition, complementation of ΔPP4/IE6 129 
with either active EspL or NleB but not NleE, restored EPEC-mediated inhibition of necroptosis 130 
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whereas inactive EspL (EspLC47S) or NleB1 (NleB1AAA) 18,19 did not (Fig. 3, Supplementary Figure 131 
6).  132 
 133 
Consistent with loss of RIPK1, ectopic expression of EspL, but not inactive EspL, blocked TNF-134 
induced expression of an NF-κB dependent luciferase reporter (Supplementary Figure 7a). In 135 
addition, EspL delivered by the T3SS in the EPEC mutant background ΔPP4/IE6 resulted in 136 
reduced IL-8 production by infected HT-29 cells (Supplementary Figure 7b).  EspL dependent loss 137 
of TRIF following EPEC infection or ectopic expression resulted in impaired interferon-β (Infβ) 138 
expression and necroptosis induced by the TLR3 and TLR4 ligands, poly(I:C) and LPS, 139 
respectively (Fig. 4a, b, Supplementary Figure 7c). Using immortalised bone marrow derived 140 
macrophages (iBMDM), we observed that EspL blocked NLRP3/RIPK3-dependent caspase-1 141 
activation induced by treatment with Cp.A/QVD 16, whereas activation of the canonical NLRP3 142 
inflammasome by nigericin was unaffected (Supplementary Figure 7d).  143 
 144 
Although EspL possessed the ability to cleave all mammalian RHIM-containing proteins, a time 145 
course comparing RIPK1 and RIPK3 cleavage suggested that RIPK1 was the preferred target 146 
during EPEC infection (Supplementary Figure 8a). In addition, cleavage likely occurred before 147 
amyloid formation as RHIM fibrils were only inefficiently cleaved by EspL compared to the 148 
monomeric proteins (Supplementary Figure 8b, c). Amyloid fibrils form the signalling scaffold of 149 
the necrosome and arise from RHIM-RHIM interactions between RIPK1 and RIPK3 4. 150 
 151 
The targeted inhibition of necroptosis and RHIM-dependent inflammatory signalling by EspL 152 
during EPEC infection suggested that the activity of EspL might aid mucosal immune evasion. Here 153 
we assessed the ability of derivatives of the EPEC-like mouse pathogen, C. rodentium to colonise 154 
wild type C57BL/6 mice. C. rodentium is a murine attaching and effacing pathogen that carries all 155 
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the conserved T3SS effector genes present in EPEC, including espL. We confirmed that EspL from 156 
C. rodentium (CREspL) cleaved RIPK1, whereas inactive CREspLC42S did not (Fig. 4c). In wild 157 
type C57BL/6 mice, we observed that an espL mutant of C. rodentium was attenuated for intestinal 158 
colonization in the resolving phase of infection suggesting that EspL promoted bacterial persistence 159 
in the gut, similar to previous findings 30 (Supplementary Figure 9). Complementation of the espL 160 
mutant with espL but not espLC47S restored intestinal colonization by C. rodentium (Fig. 4d) 161 
suggesting that the cysteine protease activity of EspL was critical to its virulence function.  Given 162 
the semi-redundant activities of EspL and NleB1 that we observed in the inhibition of necroptosis, 163 
and the fact that nleB mutants of C. rodentium also exhibit a colonization defect 18,19, further work 164 
should examine the relative contribution of each effector in vivo using an espL/nleB double mutant 165 
of C. rodentium complemented with active and inactive forms of NleB and EspL.     166 
 167 
Here we have defined EspL from EPEC as the prototypic member of a family of T3SS cysteine 168 
protease effectors and identified the targets of EspL as host RHIM-containing proteins. EspL 169 
inactivated inflammatory, inflammasome and necroptotic signalling by cleaving within the RHIM, 170 
thereby disrupting a range of host mucosal defence pathways. EspL adds to the arsenal of bacterial 171 
T3SS effectors that subvert host cell signalling and the presence of, as yet uncharacterised, EspL 172 
homologues in a broad range of bacterial pathogens suggests that this family of cysteine protease 173 
effectors constitutes a widespread virulence mechanism. 174 
 175 
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METHODS  195 
Bacterial strains, plasmids, cell lines and growth conditions 196 
The bacterial strains, plasmids and oligonucleotide primers used in this study are listed in 197 
Table S1. Bacteria were grown at 37 °C in Luria-Bertani (LB) medium, Dulbecco’s Modified 198 
Eagle’s medium (DMEM) with GlutaMAX (Gibco, NY), or Roswell Park Memorial Institute 199 
medium (RPMI) with GlutaMAX (Gibco) where indicated and supplemented with ampicillin (100 200 
μg/mL), kanamycin (100 μg/mL), nalidixic acid (50 μg/mL) or chloramphenicol (25 μg/mL) where 201 
necessary.  202 
Mouse dermal fibroblasts (MDFs) were isolated from the dermis of adult mice and 203 
immortalised with SV40 large T antigen 31. Bone marrow derived macrophages from C57BL/6 204 
mice were immortalized to generate a macrophage cell line (iBMDM) with CreJ2 virus as described 205 
previously 32.  All other cell lines were sourced from and authenticated by either the ATCC Global 206 
Bioresource Centre, or the ECACC via Sigma-Aldrich. HeLa cells, HEK293T cells, Caco-2 cells, 207 
iBMDMs, MDFs and MEFs were grown in DMEM GlutaMax (Gibco) supplemented with 10% 208 
FCS (Sigma) at 37 °C with 5% CO2. HT-29 cells were grown in Roswell Park Memorial Institute 209 
medium (RPMI) GlutaMAX (Gibco) with 10% FCS (Sigma) at 37 °C with 5% CO2. 210 
Construction of EspL expression vectors 211 
For expression in bacteria, the espL gene was amplified from EPEC E2348/69 genomic 212 
DNA by PCR using the primer pair EspLF/EspLR for cloning into pTrc99A. PCR amplification 213 
consisted of an initial denaturation step at 95 °C for 10 min, followed by 30 cycles of 94 °C for 44 214 
sec, 55 °C for 45 sec and 70 °C for 2 min followed by a final elongation step of 70°C for 10 min. 215 
The PCR product was digested with KpnI and EcoRI and ligated into pTrc99A to produce pEspL.  216 
For expression in mammalian cells, the gene encoding EspL from either EPEC E2348/69 or 217 
C. rodentium ICC169 was codon-optimised (DNA2.0), amplified using the primer pair 218 
EspLCOF/EspLCOR or EspLCRCOF/EspLCRCOR and ligated into KpnI/BamHI digested p3XFlag-Myc-219 
 10
CMV-24 to generate N-terminal 3xFlag fusions of EspL (pFlag-EspL or pFlag-CREspL). For 220 
construction of the lentiviral plasmid to generate stable inducible cell lines, codon optimised Flag-221 
EspL was amplified from pFlag-EspL and ligated into pF TRE3G PGK puro 10,29 using 222 
BamHI/XbaI. 223 
Genes encoding residues 2-549 of EPEC E2348/68 EspL and EspLC47S were amplified by 224 
PCR using pEspL and pEspLC47S as template DNA respectively, using the primer pair 225 
EspLGEXF/EspLGEXR. PCR products were digested with BamHI and NotI and ligated into the vector 226 
pGEX-2T-TEV, as previously described 33 to enable bacterial expression with an in-frame N-227 
terminal GST fusion. Insert sequences were verified by Sanger sequencing (Micromon, Monash 228 
University, Australia).  229 
Site-directed mutagenesis 230 
Site-directed mutants were generated using the Stratagene QuikChange II Site-Directed 231 
Mutagenesis Kit according to manufacturer’s protocol. pEspLC40S, pEspLC47S, pEspLH131A, 232 
pEspLD153A were generated using pEspL as template DNA and primer pairs EspL(C40S)F/EspL(C40S)R, 233 
EspL(C47S)F/EspL(C47S)R, EspL(H131A)F/EspL(H131A)R and EspL(D153A)F/EspL(D153A)R respectively. pFlag-234 
EspLC40S, pFlag-EspLC47S, pFlag-EspLH131A, pFlag-EspLD153A were generated using pFlag-EspL as 235 
template DNA and primer pairs EspL(C40S)COF/EspL(C40S)COR, EspL(C47S)COF/EspL(C47S)COR, 236 
EspL(H131A)COF/EspL(H131A)COR and EspL(D153A)COF/EspL(D153A)COR respectively. pF TREG-Flag-237 
EspLC47S was generated using pF TREG-Flag-EspL as template DNA and primer pair 238 
EspL(C47S)COF/EspL(C47S)COR. pFlag-CREspLC42S was generated using  pFlag-CREspL as template 239 
DNA and primer pair EspLC42S(CO)F/EspLC42S(CO)R. pGEX-EspLC47S was generated by PCR-240 
amplification of a cDNA encoding EPEC E2348/69 EspLC47S (pTrc-EspLC47S) using primers 241 
EspLGEXF/EspLGEXR bearing restriction sites (5’ BamHI, 3’ NotI), followed by restriction digest and 242 
ligation into the vector, pGEX-2T-TEV (pGEX-EspLC47S). pGFP-mRIPK3AAAA was generated 243 
using pGFP-mRIPK3 as template DNA and primer pair mRIPK3AAAA-F/mRIPK3AAAA-R. 244 
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Purification of GST-EspL 245 
600 mL Super broth cultures containing 100 μg/mL ampicillin were inoculated with E. coli 246 
BL21 Codon Plus transformed with GST-EspL or GST-EspLC47S expression constructs and cultured 247 
at 37 °C with shaking to OD600 of 0.6-0.8. Cultures were then cooled to 18 °C, protein expression 248 
induced by addition of 1 mM IPTG with continued shaking and incubation at 18 °C overnight. Cell 249 
pellets were resuspended in lysis buffer (200 mM NaCl, 20 mM HEPES pH 7.5, 5% w/v glycerol, 250 
0.5 mM TCEP), before lysis by sonication, elimination of debris by centrifugation at 45000 g, 0.45 251 
μm filtration of the lysate and incubation with glutathione agarose (UBP Bio) at 4 °C with agitation 252 
for 1-2 h. Beads were collected and washed with lysis buffer before incubation with 200 μg TEV 253 
protease at 20 °C for 2 h on rollers. Supernatant containing cleaved EspL or EspLC47S was 254 
concentrated by centrifugal ultrafiltration and loaded on to Superdex S200 gel filtration column pre-255 
equilibrated with gel filtration buffer (200 mM NaCl, 20 mM HEPES pH 7.5, 5% v/v glycerol). 256 
Fractions containing purified EspL or EspLC47S, as assessed by SDS-PAGE, were pooled, 257 
concentrated by centrifugal ultrafiltration to 5 mg/mL, aliquoted, snap frozen in liquid nitrogen and 258 
stored at -80 °C until required. 259 
RHIM domain protein constructs, expression and purification 260 
Synthetic genes encoding RHIM-containing regions of human RIPK1 (Q13546; residues 261 
497-583), human RIPK3 (Q9Y572; residues 387-518), human DAI/ZBP1 (Q9H171; residues 170-262 
429), human TRIF (Q8IUC6; residues 601-712) with flanking BamHI and EcoRI restriction sites 263 
were purchased from Genscript, digested with these restriction enzymes, purified by agarose gel 264 
electrophoresis and ligated individually into the pHUE vector cut with the same two restriction 265 
enzymes 34.  All expressed fusion proteins therefore consist of His6-ubiquitin-RHIM region. 266 
Successful cloning was confirmed by sequencing at AGRF (Westmead Institute) Sydney. Proteins 267 
were expressed in BL21(DE3) grown at 37 °C to an OD600 of 0.6-0.8, and induced with 0.5 mM 268 
IPTG for 3 h. Cell pellets were lysed in 6M GuHCl, 100 mM NaH2PO4, 20 mM Tris.Cl, 5 mM β 269 
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mercaptoethanol, pH 8.0, and soluble material further purified on Ni-NTA agarose under denaturing 270 
conditions, with exchange into 8 M urea, 100 mM NaH2PO4, 20 mM Tris, 5 mM β mercaptoethanol 271 
at pH 6.0 for washing and pH 4.0 for elution from the Ni-NTA agarose. 272 
Generation of stable inducible cell lines in mouse dermal fibroblasts (MDF) and immortalized 273 
bone marrow derived macrophages (iBMDM) 274 
HEK293T cells were seeded at 2 x 105 cells per 10 cm culture dishes and 24 h later were co-275 
transfected with 10 μg of either pF TRE3G-Flag-EspL or pF TRE3G-Flag-EspLC47S along with the 276 
helper plasmids pMDL-RRE, pRSV-REV and pVSV-g (5, 2.5 and 3 μg, respectively) using 277 
Effectine Transfection Reagent (QIAGEN) for a further 24 h. Culture media was then changed and 278 
the cells were incubated for a further 48 h for virus production. Polybrene (5 μg/mL) (Sigma) was 279 
added to the cell culture dishes and the virus-containing supernatant was collected and passed 280 
through a 0.45 μM filter. Virus-containing supernatant was added to either MDF monolayers or 281 
iBMDM monolayers and incubated at 37 °C with 5% CO2 for 24 h. Infected cells were selected for 282 
using increasing concentrations of up to 5 μg/mL of puromycin (Sigma) for at least one week. 283 
Expression of Flag-EspL or Flag-EspLC47S in either MDFs or iBMDMs was tested by adding 20 284 
ng/mL doxycycline at varying time points followed by immunoblot using anti-Flag antibodies. 285 
Construction of Citrobacter rodentium espL mutant  286 
A 325 bp upstream region of espL was amplified using primer pair Up-EspL-Fw/BamHI-287 
Up-EspL-Rv, and a 500 bp downstream region of espL was amplified using primer pair BamHI-288 
Down-EspL-Fw/Down-EspL-Rv. Both fragments were then digested with BamHI, ligated together, 289 
and cloned into pGEMT. The non-polar aphT cassette 35 was then inserted into the BamHI site 290 
between the two fragments and the orientation of the aphT cassette ascertained by PCR. This 291 
construct was then amplified using the primer pair Up-EspL-Fw/Down-EspL-Rv. The PCR 292 
products were electroporated into ICC169 containing pKD46 encoding lambda red recombinase 36. 293 
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Transformants were selected on kanamycin agar plates and espL deletion confirmed by PCR 294 
(Check-EspL-UP-Fw /Down-EspL-Rv) and DNA sequencing. 295 
cis complementation of the Citrobacter rodentium espL mutant 296 
The Citrobacter rodentium espL mutant was cis complemented with either WT espL or 297 
espLC42S using the transgene insertion method previously described 37. Briefly, the espL gene with 298 
its native promoter was amplified from C. rodentium ICC169 genomic DNA template by PCR 299 
using primers EspLCRF1/EspLCRR1, and then ligated into the XmaI/XhoI restriction sites of the 300 
pGRG36 vector. The pGRG36-EspLC42S construct was generated by site-directed mutagenesis. The 301 
pGRG36-EspL construct was used as template DNA and amplified by PCR using primers 302 
EspLC42SF/EspLC42SR. The resulting plasmid was digested with DpnI at 37 °C overnight before 303 
transformation into the appropriate E. coli strain.  304 
The pGRG36-EspL and pGRG36-EspLC42S constructs were confirmed by PCR using 305 
primers Tn7F/Tn7R, then electroporated into electrocompetent C. rodentium espL mutant cells and 306 
selected for using 100 ug/mL ampicillin and incubated at 30 °C overnight. Transformants were 307 
streaked out once, then grown overnight in LB without antibiotics at 30 °C. Dilutions were prepared 308 
and plated on LB and grown overnight at 42 °C. Transposition of the Tn7:espL/espLC42S into the 309 
attTn7 insertion site in the C. rodentium espL mutant chromosome was confirmed by the absence of 310 
the ampicillin resistance marker and PCR using primers CRseqF/CRseqR. 311 
Construction of EPEC single and triple deletion mutants 312 
To construct the EPEC E2348/69 espL deletion mutant strain, 342-bp and 331-bp fragments 313 
were amplified from 5’ and 3’ flanking sites of espL using oligonucleotides EspL5’F/ EspL5’R and 314 
EspL3’F/ EspL3’R. The plasmid pKD4 was used as template DNA to amplify the kanamycin cassette 315 
using oligonucleotides pKD3-4F and pKD3-4R. Overlapping PCR was used to assemble the espL 316 
flanking regions with the kanamycin cassette construct using oligonucleotides EspL5’F and EspL3’R. 317 
Lambda red mediated recombination 36 was used to replace the wild type allele with the kanamycin 318 
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resistance cassette. The cassette was electroporated into wild-type EPEC E2348/69 and positive 319 
clones were selected for on LB agar with 25 μg/mL kanamycin. To construct the EPEC E2348/69 320 
espLnleBE deletion mutant, a 368-bp fragment was amplified from 5’ flanking site of nleB using 321 
oligonucleotides NleB5’F/ NleB5’R and 550-bp fragment was amplified from 3’ flanking site of nleE 322 
using oligonucleotides NleE3’F/ NleE3’R. The plasmid pKD3 was used as template DNA to amplify 323 
the chloramphenicol cassette using oligonucleotides pKD3-4F and pKD3-4R. Overlapping PCR was 324 
used to assemble the nleB and nleE flanking regions with the chloramphenicol cassette construct 325 
using oligonucleotides NleB5’F and NleE3’R. Lambda red mediated recombination 36 was used to 326 
replace the wild type allele with the chloramphenicol resistance cassette. The cassette was 327 
electroporated into EPEC E2348/69 espL mutant cells and positive clones were selected for on LB 328 
agar with 5 μg/mL chloramphenicol. Deletions were confirmed by PCR with a combination of 329 
primers from outside and inside the altered region. Attachment and pedestal formation by parental 330 
and mutant strains were confirmed using fluorescence actin staining. 331 
EPEC infection  332 
Cell lines of HeLa, Caco-2, MDF and HT-29 cells are maintained in our laboratory and 333 
regularly tested for mycoplasma contamination. Two days prior to infection HeLa, Caco-2, MDF or 334 
HT-29 cell monolayers were seeded into 24 well tissue culture trays. One day prior to infection 335 
derivatives of EPEC were inoculated into LB broth and grown with shaking at 37 °C overnight. On 336 
the day of infection, overnight cultures of EPEC were sub-cultured 1:75 in DMEM GlutaMAX 337 
(Gibco) or RPMI GlutaMAX (Gibco) and grown statically for 3 h at 37 °C with 5% CO2. Where 338 
necessary, cells were induced with 1 mM isopropyl-Β-D-thiogalactopyranoside IPTG (Sigma) 30 339 
min prior to infection. Cells were washed twice with PBS and infected with EPEC grown to an 340 
OD600nm of 0.03 for 1-3 h (depending on the experiment). When required, the inhibitors MG132 341 
(Sigma) (10 μM), antipain (Sigma) (10, 20 or 40 μg/mL), z-VAD-FMK (Abcam) (25 μM), or z-FA-342 
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FMK (Abcam) (10, 20 or 40 μM) were added to the cells 1 hr prior to infection and kept on for the 343 
duration of the infection. 344 
Transfection 345 
 All transfections were performed in HEK293T cells using Fugene® 6 (Promega) 346 
transfection reagent. Cells were seeded into 24 well tissue culture trays and transfected 24 h later 347 
with 1μg DNA for a period of ~18 h.  348 
Fluorescent actin stain 349 
HeLa cells were seeded on coverslips and infected as previously described. After infection, 350 
cells were washed with PBS, fixed in 4 %PFA in PBS for 30 min and permeabilised in 1% Triton 351 
X-100 for another 30 min. Cells were then washed twice with PBS and stained with 4’,6-diamidino-352 
2-phenylindole (DAPI, Invitrogen) at 0.5 mg/mL and Phalloidin-Tetramethylrhodamine B 353 
isothiocyanate (Sigma) in 3% BSA/PBS for 30 min. Coverslips were mounted onto microscope 354 
slides with Prolong Gold anti-fade reagent (Invitrogen). Images were acquired using a Zeiss 355 
confocal laser scanning microscope with a 1003/EC Epiplan-Apochromat oil immersion objective. 356 
Immunoblot analysis 357 
 For immunoblot analysis following EPEC infection, transfection or induction of stable cell 358 
lines, cells were collected and lysed in cold lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH 359 
7.4, 1 mM EDTA, 150 mM NaCl) with Complete Protease Inhibitor (Roche), 2 mM Na3VO4, 10 360 
mM NaF, 1 mM PMSF and incubated on ice for 10 min to complete lysis. Samples were then 361 
pelleted at 4 °C by centrifugation and the supernatants added to 4×Bolt® LDS Sample Buffer 362 
(Thermo Fisher), heated to 70 °C for 10 min and resolved on Bolt® 4-12% Bis-Tris Plus Gels 363 
(Thermo Fisher) by PAGE. Proteins were transferred to nitrocellulose membranes using an iBlot2 364 
Gel Transfer Device (Thermo Fisher) and probed with one of the following primary antibodies: 365 
mouse monoclonal anti-RIPK1 (38/RIP) (BD Transduction Laboratories), mouse monoclonal anti-366 
RIPK2/RICK (25/RIG-G) (BD Transduction Laboratories), rabbit polyclonal anti-RIPK3 (Abcam) 367 
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(for HT-29 cells), rabbit polyclonal anti-RIPK3 (ProSci) (for MDF cells) or rabbit polyclonal anti-368 
TRIF (Cell Signaling), mouse monoclonal anti-Flag M2-HRP (Sigma), mouse monoclonal anti-369 
GFP (7.1 and 13.1) (Roche), mouse monoclonal anti-β-actin (AC-15) (Sigma), mouse monoclonal 370 
anti-TRADD (7G8) (Cell Signaling), rabbit polyclonal anti-TRAF2 (Cell Signaling), monoclonal 371 
rat anti-mouse MLKL (WEHI-3H1) (WEHI, made in-house), mouse monoclonal anti-TEM1 β-372 
lactamase (8A5.A10) (QED Bioscience) diluted in TBS with 5% BSA (Sigma) and 0.1% Tween 373 
(Sigma). Proteins were detected using anti-rabbit or anti-mouse IgG secondary antibodies 374 
conjugated to horseradish peroxidase (PerkinElmer) diluted in TBS with 5% BSA (Roche) and 375 
0.1% Tween (Sigma) and developed with enhanced chemiluminescence (ECL) western blotting 376 
reagent (Amersham). Images were visualised using an MFChemiBis imaging station (DNR, Israel). 377 
At least three biological replicates were performed for all experiments. 378 
Cell viability assays (MTT and propidium iodide staining) 379 
For analysis of cell viability using MTT assays, immortalised mouse bone marrow-derived 380 
macrophages (iBMDM) stably expressing either EspL or EspLC47S were seeded into 24 well tissue 381 
culture plates (Corning) for 18-24 h before being left untreated or treated with 20 ng/mL of LPS (E. 382 
coli 0111:B4) (Sigma) or 50 μg/mL Poly I:C (for iBMDMs) (Sigma) or 10 μg/mL high molecular 383 
weight Poly I:C (InvivoGen, CA, USA) and 10 μM z–VAD-FMK (Abcam) for a further 18 h. The 384 
cells were washed once with PBS and replaced with DMEM containing 0.1 μg/mL 3-(4,5-385 
Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) (Sigma) for 1 h, after which the 386 
medium was removed and 100 μL of dimethyl-sulfoxide (DMSO; Sigma) was added to each well. 387 
After thorough mixing on an orbital shaker for 1 min, the absorbance at 540 nm for each well was 388 
obtained using a CLARIOstar microplate reader (BMG Labtech, Germany). Results were obtained 389 
from at least 3 independent experiments. 390 
For analysis of cell viability by propidium iodide (PI) staining of HT-29 monolayers, cells 391 
were seeded into 24 well tissue culture plates with sterile glass coverslips and 48 h later were 392 
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infected with EPEC derivatives as previously mentioned for 2.5 h followed by 4 h incubation in 393 
media supplemented with 50 μg/mL gentamicin and 20 ng/mL TNF (Calbiochem), 500 nM 394 
compound A (Cp. A, Tetralogic), 25 μM z-VAD-FMK (Abcam). PI (50 μg/mL) (Sigma) was added 395 
for the final 15 min of treatment. Cells were then fixed in 3.7% (wt/vol) formaldehyde (Sigma) in 396 
PBS for 10 min and permeabilised with 0.2% Triton (Sigma) for 4 min. 4’, 6-diamidino-2-397 
phenylindole (DAPI; Invitrogen) was applied at 0.5 μg/mL in PBS for 10 min. Cells were washed 398 
with PBS three times and coverslips were mounted onto microscope slides with Prolong Gold anti-399 
fade reagent (Invitrogen). Images were acquired using a Zeiss confocal laser-scanning microscope 400 
with a 100x/EC Epiplan-Apochromat oil immersion objective. Duplicate coverslips were blinded 401 
for counting of PI positive cells, and results were obtained from at least 3 independent experiments. 402 
For analysis of cell viability by PI staining and confocal microscopy in MDF cells, EspL 403 
and EspLC47S expressing lines were induced with 20 ng/mL doxycycline for 2 h followed by 4 h 404 
incubation in media supplemented with 20 ng/mL TNF (Calbiochem), 500 nM Cp. A (Tetralogic), 405 
25 μM z-VAD-FMK (Abcam). PI, DAPI staining and confocal microscopy were carried out as 406 
described above. Duplicate coverslips were blinded for counting of PI positive cells, and results 407 
were obtained from at least 3 independent experiments. 408 
For analysis of cell viability by PI staining and flow cytometry, MDF-EspL and MDF-409 
EspLC47S, cell lines were induced with 10 ng/mL doxycycline for 1 h followed by 24 h incubation in 410 
media supplemented with 100 ng/mL hTNF-Fc produced in house (WEHI), 500 nM Cp. A 411 
(Tetralogic), 50 μM QVD-OPH (Abcam). Cell death was assessed with PI staining (1 ug/mL) and 412 
quantified using a BD FACSCalibur flow cytometer. Data was analysed using the WEASEL Flow 413 
Cytometry Software. 414 
Monitoring MLKL complex formation using BN-PAGE 415 
For MDF cells, 5 x 105 cells (wild type, stably expressing inducible Flag-EspL or Flag-416 
EspLC47S) were used to seed each well of a 6 well tissue culture plate and allowed to attach 417 
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overnight. Cells were stimulated with 0.5 μg/mL doxycycline for 2 h to induce Flag-EspL 418 
expression prior to the addition of 100 ng/mL hTNF-Fc produced in house (WEHI), 500 nM Cp. A 419 
(Tetralogic), 25 μM z-VAD-FMK (Abcam) for a further 4 h to induce necroptosis. For HT29 cells, 420 
5 x 105 cells were plated in each well of a six well plate and allowed to attach for 48 h. Cells were 421 
infected with derivatives of EPEC E2348/69 for 2.5 h followed by stimulation with 20 ng/mL TNF 422 
(Calbiochem), 500 nM Cp. A (Tetralogic), 25 μM z-VAD-FMK (Abcam) for a further 5 h to induce 423 
necroptosis. Cells were harvested by scraping and permeabilised in MELB buffer (20 mM HEPES 424 
(pH 7.5), 100 mM KCl, 2.5 mM MgCl2, 100 mM sucrose, 0.025% digitonin (BIOSYNTH, Staad, 425 
Switzerland) 2 μM N-ethyl maleimide, Complete Protease Inhibitor (Roche) and PhosSTOP 426 
phosphatase inhibitor cocktail (Roche)). Cytosolic and crude membrane fractions were separated by 427 
centrifugation and the crude membrane fraction further solubilized in MELB buffer containing 1% 428 
digitonin and clarified by centrifugation. Digitonin was added to the cytosolic fraction (final 1% 429 
w/v) and fractions were resolved on a 4-16% Bis-Tris Native PAGE gels (Thermo Fisher), 430 
transferred to PVDF and probed for rabbit anti-human phospho-MLKL (Abcam), monoclonal rat 431 
anti-mouse MLKL (WEHI-3H1) (WEHI, made in house), rabbit polyclonal anti-VDAC1 432 
(Millipore) and rabbit polyclonal anti-GAPDH (Cell Signaling). 433 
Inflammasome activation 434 
 iBMDMs (WT, EspL or EspLC47S) were seeded in 12 well tissue culture treated plates and 435 
treated with 50 ng/mL ultra-pure LPS (Invivogen) for 2 h then 1 μg/mL doxycycline (Sigma) added 436 
for an additional 2 h. Cells were subsequently stimulated with 1 μM Cp.A (Tetralogic 437 
pharmaceuticals) and/or 15 μM QVD-Oph (RnD Systems) for 6 h or 10 μM Nigericin (Sigma) for 1 438 
h. Cell supernatants and lysates were analysed by western blot. Primary antibodies used were 439 
mouse monoclonal anti-Flag M2-HRP (Sigma), mouse monoclonal caspase-1 (casper-1) 440 
(Adipogen), mouse monoclonal anti-RIPK1 (38/RIP) (BD Transduction), rabbit polyclonal RIPK3 441 
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(Axxora; PSC-2283-C100) and mouse monoclonal anti-β-actin (AC-15) (Sigma). All antibody 442 
dilutions were performed in 5% skim milk/0.1% PBS Tween. 443 
IL-8 secretion assay 444 
For analysis of IL-8 secretion, HT-29 cell monolayers were infected for 3 h before being 445 
incubated for 8-12 h in media supplemented with 50 μg/mL gentamicin with or without 20 ng/mL 446 
TNF (Calbiochem, EMD4Biosciences, USA). Following this, the HT-29 cell supernatant was 447 
collected and either used immediately or stored at -20 °C for subsequent analysis of IL-8 secretion. 448 
IL-8 secretion was measured using the Human IL-8 ELISA MAX Deluxe Set (Biolegend, CA, 449 
USA) according to the manufacturer’s instructions.  450 
qRT-PCR 451 
Samples for qRT-PCR experiments were DNAse treated using Ambion TURBO DNA-free 452 
kit and cDNA synthesis was completed using the iScriptTM cDNA synthesis kit (Bio-Rad). qRT-453 
PCR was performed using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad) according 454 
to manufacturer’s instructions and gene specific primers used are listed in Table S1. Samples were 455 
loaded onto MicroAmp® Optical 384-well reaction plates (Life technologies) in duplicate and run 456 
on the ABI Quant Studio 7 according to manufacturer’s instructions.  Melting curve analysis was 457 
used to ensure there were no primer dimers. Negative controls included both a no-reverse 458 
transcriptase control and a no cDNA control. Data were analysed by the threshold cycle method 459 
(ΔΔCt method) 38 and normalised to 18S abundance. All data are represented as fold induction 460 
relative to gene expression in uninduced, unstimulated cells or uninfected, unstimulated cells. All 461 
experiments were carried out in triplicate.  462 
Beta-lactamase translocation assay 463 
HeLa cells were seeded in black 96 well trays with transparent well bottom (Greiner Bio-464 
One) for 16 to 24 h prior to infection. On the day of infection, EPEC strains with derivatives of 465 
pCX340 were cultured as previously described. 2.5 mM Probenecid (Sigma) and 1 mM IPTG 466 
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(Sigma) were added to bacterial cultures for the last 45 min before infection. HeLa cells were 467 
loaded with CCF2/AM substrate following manufacturer’s instructions (Invitrogen) and incubated 468 
at room temperature in the dark for one hour. 15 minutes before infection, cells were transferred 469 
back to 37 °C 5% CO2. Infection was carried out using 50 μl of bacterial culture with an OD600 of 470 
0.1 for 60 min at 37 °C in 5% CO2. Translocation was measured as a ratio of 471 
Emission450nm:Emission520nm using a CLARIOstar Omega microplate reader (BMGLabtech) using 472 
triplicate wells for each strain. 473 
Dual-luciferase reporter assay 474 
For the NF-κB dual-luciferase assay, HeLa cells were seeded into 24-well trays (Corning) 475 
and co-transfected with derivatives of p3xFlag-Myc-CMV-24 (0.4 μg), 0.05 μg of pRL-TK 476 
(Promega, Madison WI, USA) and 0.2 μg of pNF-κB-Luc (Clontech, Palo Alto CA, USA). 477 
Approximately 24 h post-transfection, cells were left untreated or stimulated with 20 ng/mL 478 
TNF(Calbiochem, La Jolla, CA) for 6 h. Firefly and Renilla luciferase levels were measured using 479 
the Dual-luciferase reporter assay system (Promega) in a CLARIOstar Omega microplate reader 480 
(BMGLabtech, Germany). The expression of firefly luciferase was normalised for Renilla luciferase 481 
measurements and Luciferase activity was expressed relative to unstimulated p3xFlag-Myc-CMV-482 
24-transfected cells. 483 
In vitro cleavage assays 484 
Purified proteins were diluted out of urea-containing buffer and incubated in 100 μl of 485 
reaction buffer (25 mM NaH2PO4, 150 mM NaCl, 0.5 mM DTT, pH 7.4) at a concentration of 20 486 
μM (RHIM proteins) or 0.9 μM (EspL/EspLC47S) for 1 hour at 37 °C. Sample buffer was then added 487 
to incubated proteins, before the samples were boiled and subjected to SDS-PAGE on Nu-PAGE 4-488 
12% Bis-Tris polyacrylamide gels. The gels were stained with Coomassie Blue Stain and imaged 489 
with a GelMax imager (UVP, Analytik Jena, USA). 490 
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To compare the cleavage of RHIM-containing protein in monomeric and fibrillar forms, 491 
10 μg EspL was added to 200 μL of 20 μM of His-Ub-RIPK3 in 25 mM NaH2PO4, 150 mM NaCl, 492 
0.5 mM DTT, pH 7.4 immediately following dilution of His-Ub-RIPK3 from 8M urea-containing 493 
buffer or after incubation of the diluted His-Ub-RIPK3 for 225 min at 37 °C to allow fibril 494 
formation. Samples were subsequently incubated with EspL at 37 ºC for 1 h. For both ‘monomer’ 495 
and ‘fibril’ samples, 100 μL was pelleted at 16,000g for 10 min. The supernatant was collected as 496 
the soluble fraction and the pellet was resuspended with 100 μL of 8M urea, pH 4.0. Samples were 497 
subjected to SDS-PAGE and stained with Coomassie Blue Stain for visualisation and imaging as 498 
above. 499 
Thioflavin-T (ThT) assays 500 
 501 
Thioflavin-T (ThT) assays were used to monitor fibril formation. 20μM of recombinant 502 
RHIM containing His-Ub-RIPK3 was incubated in buffer (25 mM NaH2PO4, 150 mM NaCl, 0.5 503 
mM DTT, pH 7.4, 40 μM ThT) in a Costar 96-well plate (Corning) at 37 °C for 3.75 hours inside a 504 
POLARstar Omega microplate reader (BMGLabtech). Samples were excited at 440 nm and ThT 505 
fluorescence emission was measured at 480 nm every 60 seconds. Fibril formation was evident after 506 
225 min. To test the cleavage of RHIM fibrils by EspL, 500 μl of 20 μM of His-Ub-RIPK3 was 507 
dialysed against 1 L of dialysis buffer (25 mM NaH2PO4, 150 mM NaCl, 0.5 mM DTT, pH 7.4) for 508 
24 h at room temperature. 100 μl of ‘fibril’ sample was then incubated with 0.9 μM purified EspL, 509 
vortexed briefly and incubated at 37 ºC for either 1 or 2 h. For both ‘monomer’ and ‘fibril’ samples, 510 
100 μl was pelleted at 16,000 g for 10 min. The supernatant was collected as the soluble fraction 511 
and the pellet was resuspended with 100 μl of 8M urea, pH 4.0. Samples were subjected to SDS-512 
PAGE and stained with Coomassie Blue Stain for visualisation and imaging as previously 513 
mentioned. 514 
 515 
 516 
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Reverse-phase HPLC 517 
200–1000 μL of purified RHIM proteins at a concentration of 20 μM were incubated with or 518 
without 0.9 μM of purified EspL for 1 hour at 37 °C. Proteins were then analysed by RP-HPLC 519 
using a C8 VYDAC column running in MilliQ water containing 0.1% TFA, 10% methanol and 520 
eluted with an increasing gradient of acetonitrile. Peaks were collected and lyophilized for further 521 
analysis by N-terminal sequencing or LC-MS/MS. 522 
N-terminal sequencing 523 
N-terminal sequencing was performed by the Australian Proteome Analysis Facility (APAF) 524 
at Macquarie University, New South Wales, Australia. 525 
Characterisation of His6-Ub-RIPK3 and His6-Ub-TRIF cleavage products by intact mass 526 
spectrometry analysis  527 
Characterisation of RIPK3 and TRIF cleavage products by intact mass spectrometry were 528 
performed on samples prepared by in vitro cleavage assay and purified by RP-HPLC as described 529 
above. 530 
Time-of-flight tandem mass spectrometry 531 
Mass measurements of the intact protein ions and ETD and CID MS/MS were performed on the 532 
high resolution, high mass accuracy quadrupole time-of-flight (qTOF) mass spectrometer (maXis II 533 
UHR qTOF, Bruker Daltonics, Bremen, Germany) equipped with an electrospray ion (ESI) source 534 
for the direct-infusion method. For the direct-infusion experiments a flow rate of 180 μL/min was 535 
provided by a syringe pump (KdScientific, Holliston, MA, USA) using a 25 μL syringe (SGE 536 
Analytical Sciences, VIC, AUS).  The following settings were applied: capillary voltage of 4.5 kV, 537 
end plate offset of 500 V, mass range of m/z 450 to 2500, dry gas of 4.0 L/min, and drying 538 
temperature of 220 °C. Nano-ESI infusion was performed using HPLC fractions which were 539 
reconstituted in 20 μl of water and diluted 1:10 with 50% acetonitrile: 50% water containing 1% 540 
formic acid. 541 
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Data analysis 542 
The MS and MS/MS spectra were analyzed using a dedicated top-down data analysis procedure. 543 
Briefly, precursor and product ion mass spectra were summed over the infusion time in each MS 544 
and MS/MS experiment with Data Analysis software version 4.3 (Bruker Daltonics). Automatic 545 
data analysis was performed by deisotoping keeping only the monoisotopic masses followed by 546 
charge state deconvolution (SNAP 2 algorithm). The obtained mass list of product ions was 547 
matched on the predicted cleaved mRIPK3 sequence to determine the product ion identity and the 548 
sequence coverage using the observed mass of the precursor ion.  549 
Necroptosis experiments. The human epithelial cell line, HT-29, as well as mouse dermal 550 
fibroblasts (MDF) and immortalised bone marrow derived macrophages (iBMDMs) either infected 551 
with derivatives of EPEC E2348/69 or engineered to express EspL derivatives were used to 552 
examine the effect of EspL on necroptosis. Necroptosis was induced by treatment with 1) 20 ng/mL 553 
TNF, 500 nM Cp.A and 25 μM z-VAD-FMK or 50 μM QVD-OPH or 2) 20 ng/mL of LPS (E. coli 554 
0111:B4) and 10 μM z–VAD-FMK or 3) 50 μg/mL Poly I:C (for iBMDMs) or 10 μg/mL high 555 
molecular weight Poly I:C (for HT-29) and 10 μM z–VAD-FMK. Cell viability was assessed by 556 
reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) or by 557 
propidium iodide (PI) uptake. MLKL complex formation and membrane translocation were 558 
examined by Blue native PAGE of cell membrane and cytosolic fractions and immunoblotting 559 
using antibodies to MLKL and phospho-MLKL.  560 
Protein sequence alignment and phylogenetic tree 561 
RHIM domain alignment for human and mouse RIPK1, RIPK3, TRIF and DAI was 562 
performed by Clustal Omega and ESPript339. Accession numbers (same order as displayed in Fig. 563 
2c) NP_003795, NP_033094, NP_006862, NP_064339, NP_891549, NP_778154, NP_110403, 564 
NP_067369, NP_001153889, NP_001132991. For comparison of the cysteine protease motif, 565 
sequences were identified through BLAST using EspL from EPEC E2348/69 as a reference. A 566 
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section of the proteins identified by BLAST were aligned using Clustal Omega and presentation of 567 
alignment performed using ESPript3 39. Accession numbers (same order as displayed in 568 
Supplementary Figure Fig. 2) CAS10778, AIG70345, WP_012905388, WP_031942474, 569 
WP_024259347, ENZ84489, WP_023263817, WP_015872003, WP_020957625, CCA83579, 570 
WP_009667375, CDG86051, WP_004389152, WP_004714204, WP_019080404, AHK18540, 571 
WP_002211641, AIN16488. 572 
A set of protein sequences was curated based on the identification of homologues of EspL 573 
from EPEC E2348/69. BLAST 25 was used to compare these protein sequences to the nr database 574 
and nt database (downloaded on 31st July from ftp://ftp.ebi.edu.au/pub/databases/ncbi/blast/db/) 575 
with blastp and tblastn respectively to identify additional proteins. The subsequent results were 576 
filtered on the E scores of 0.0 and length, and reduced to unique accession (removing duplicates). 577 
The nucleotide sequences were translated into amino acid sequences with EMBOSS 40 and the 578 
protein sequences were aligned with Muscle 41. The best fitting protein model was determined using 579 
the Perl script ProteinModelSelection.pl available at http://sco.hits.org/exelixis/web/software/raxml/ 580 
for RAxML 42. One hundred pseudo-replicate RAxML analyses were run three times using the best-581 
fitting substitution model, PROTGAMMA VF. The best scoring Maximum Likelihood tree was 582 
selected and midpoint rooted in Dendroscope 43. The following accession numbers were used for 583 
phylogenetic analyses; CAS10778.1, AIG70345.1, CBG87854.1, ACR69900, CP001064, 584 
CP011417, LM996972, LM997319, CP001064, Z54194, WP_ 028120439, LM996116, 585 
WP_028120664, WP_038348374, AJ303141 LM996576, AP010958, LM995478, LM995537, 586 
LM996653, LM997233, LM997407, LM995613, LM997087, WP_001121612, WP_001121619, 587 
WP_001121621, WP_033810450, WP_044863368, AAJV00000000, AIAN00000000, FM986650, 588 
AP010960, LM996367, EHW09036, EHW21689, WP_001121623, WP_001121627, 589 
WP_001121746, WP_001121747, WP_001121748, WP_021824236, WP_023981847, 590 
WP_032272532, WP_032273780, AIHA00000000, WP_032349748, AIHB00000000, 591 
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AIHD00000000, AIHE00000000, AAJX00000000, AIBC00000000, LN554915, LM996042, 592 
LM996071, LM996922, WP_001121620, WP_032210130, AKNI01000047, AIAL00000000, 593 
AIAO00000000, AIGY00000000, AIGZ00000000, AIBX00000000, CP006262, CP007133, 594 
LM996313, LM996458, CP007136, LM995993, LM996803, LM997001, WP_001121622, 595 
AIAI00000000, AIAX00000000, AF453441, AIBD00000000, CP008805, CP001164, CP001368, 596 
CP001925, CP010304, EHV10408, WP_001121626, WP_024256897, WP_032208682, 597 
AIAQ00000000, LM995690, LM995751, LM995947, AJ277443, FM201463, LM995831, 598 
LM996694, LM997125, EHW62569, WP_001121617, WP_032345473, WP_045889142, 599 
AICF00000000, AIAC00000000, AIGK00000000, AIGN00000000, AIGO00000000, 600 
AIAG00000000, AIGL00000000, AIGM00000000, AIBT00000000, AIBR00000000, 601 
AIBV00000000, AIGX00000000, WP_001121628, CP001846, CP003109, WP_001121608, 602 
WP_001121609, WP_001121624, AIAH00000000, AIAD00000000, ADUL01000000, 603 
AIFD00000000, AIAE00000000, AIFS00000000, AIFT00000000, AIFU00000000, 604 
AIFQ00000000, FM986652, LM996749, CDG86051, WP_038497945, WP_009667375, 605 
CCA83579, FP885907, AEG72234, CBJ36034, CEJ16658, EUJ11993, WP_003265371, 606 
WP_003274329, WP_013209029, WP_039553678, WP_042549988, WP_042592182, 607 
WP_043947056, ENZ84489, CP000037, CP001062, WP_012421777, CP000035, CP006737, 608 
ADA76828, EFP73031, EFW48342, WP_000608472, WP_005015229, WP_011379052, 609 
AY879342, NG_035859, NG_035867, AF348706, AF386526, AL391753, AY879342, CP001384, 610 
CP007038, Z54211, CAA90938, EIQ30821, WP_005058548, WP_005061014, WP_005065444, 611 
WP_005115993, WP_005117432, WP_010921597, WP_010921642, WP_015060143, 612 
WP_024259347, WP_025746267, WP_025748914, WP_025759433, WP_025766126, 613 
WP_031942474, WP_039060413, WP_040234710, WP_047204882, WP_047204897, CP000039, 614 
CP011423, HE616529, WP_005041841, WP_005138925, WP_024261348, CFB70006, 615 
CFQ67145, CNC44257, CRE36360, WP_019080404, CFR06093, WP_004389152, CP000305, 616 
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CP001585, CP001589, CP001608, CP002956, CP009492, CP009704, CP009723, CP009785, 617 
CP009836, CP009844, CP009973, CP009996, CP010023, CP010293, AE009952, AE017042, 618 
AL590842, CP000308, CP001593, CP009840, CP009906, CP009991, KGA51839, 619 
WP_002211641, WP_045123609, BX936398, CP001048, CP009757, CP009780, CP009786, 620 
CP010067, CP000950, CP008943, CP009712, CP009759, CP009792, CFV36814, CNG55237, 621 
CNJ16181, WP_011193035, WP_012104544, WP_012303595, ESJ22116.1, WP_032466541, 622 
WP_038400874, WP_004714204, CP007230, CNC46702, WP_025381344, WP_006576111.1 623 
Mouse infection studies 624 
All animal experimentation was approved by the Melbourne University Animal Ethics 625 
Committee. All mice used were of a C57BL/6 background and were age matched as best as possible 626 
between 5-8 weeks pre-infection. No calculation was used to assess the number of animals required. 627 
Male and female mice were allocated to experimental groups to ensure even distribution of age, sex 628 
and weight and investigators were not blinded to the allocation. Citrobacter rodentium was cultured 629 
in LB broth overnight before centrifugation and re-suspension in PBS to a concentration of ~5 x 109 630 
cells/mL. C57BL/6 (5- to 8 weeks old) were inoculated by oral gavage with 200 μl of 631 
approximately 1 x 109 c.f.u of C. rodentium. The viable count of the inoculum was determined 632 
retrospectively by plating dilutions of the inoculum on plates with appropriate antibiotics. Mice 633 
were weighed every 2 days and faeces collected every 2 or 4 days for enumeration of c.f.u. The 634 
viable count per g of faeces was determined by plating serial dilutions of faeces onto media 635 
containing selective antibiotics. 636 
Statistical analysis. All statistical analyses were performed using GraphPad Prism version 6.0. 637 
Statistical tests used were unpaired two-tailed Student’s t-test for pairwise comparisons between 638 
groups or One-way ANOVA with Holm-Sidak’s Test for multiple comparisons where indicated. 639 
Variance was similar in all comparisons. Differences in faecal counts of CR from mice and 640 
 27
diarrhoea and pathology scores were assessed using a Mann Whitney U test, where normal 641 
distribution was not assumed. P< 0.05 was considered to be significant.  642 
Data availability. The data that support the findings of this study are available from the 643 
corresponding author upon request 644 
  645 
 28
 646 
References 647 
1 Sun, X., Yin, J., Starovasnik, M. A., Fairbrother, W. J. & Dixit, V. M. Identification of a 648 
novel homotypic interaction motif required for the phosphorylation of receptor-interacting 649 
protein (RIP) by RIP3. J Biol Chem 277, 9505-9511 (2002). 650 
2 Kaiser, W. J. & Offermann, M. K. Apoptosis induced by the toll-like receptor adaptor TRIF 651 
is dependent on its receptor interacting protein homotypic interaction motif. J Immunol 174, 652 
4942-4952 (2005). 653 
3 Rebsamen, M. et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction 654 
motifs to activate NF-kappaB. EMBO Rep 10, 916-922 (2009). 655 
4 Li, J. et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex 656 
required for programmed necrosis. Cell 150, 339-350 (2012). 657 
5 Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 658 
311-320 (2015). 659 
6 Micheau, O. & Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two 660 
sequential signaling complexes. Cell 114, 181-190 (2003). 661 
7 Holler, N. et al. Fas triggers an alternative, caspase-8-independent cell death pathway using 662 
the kinase RIP as effector molecule. Nat Immunol 1, 489-495 (2000). 663 
8 Cho, Y. S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates 664 
programmed necrosis and virus-induced inflammation. Cell 137, 1112-1123 (2009). 665 
9 He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to 666 
TNF-alpha. Cell 137, 1100-1111 (2009). 667 
10 Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch 668 
mechanism. Immunity 39, 443-453 (2013). 669 
11 Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling 670 
downstream of RIP3 kinase. Cell 148, 213-227 (2012). 671 
12 Cai, Z. et al. Plasma membrane translocation of trimerized MLKL protein is required for 672 
TNF-induced necroptosis. Nat Cell Biol 16, 55-65 (2014). 673 
13 Hildebrand, J. M. et al. Activation of the pseudokinase MLKL unleashes the four-helix 674 
bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad 675 
Sci U S A 111, 15072-15077 (2014). 676 
14 Kaiser, W. J. et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J 677 
Biol Chem 288, 31268-31279 (2013). 678 
15 Upton, J. W., Kaiser, W. J. & Mocarski, E. S. DAI/ZBP1/DLM-1 complexes with RIP3 to 679 
mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus 680 
vIRA. Cell Host Microbe 11, 290-297 (2012). 681 
16 Lawlor, K. E. et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the 682 
absence of MLKL. Nat Commun 6, 6282 (2015). 683 
17 Giogha, C., Lung, T. W., Pearson, J. S. & Hartland, E. L. Inhibition of death receptor 684 
signaling by bacterial gut pathogens. Cytokine Growth Factor Rev 25, 235-243 (2014). 685 
18 Pearson, J. S. et al. A type III effector antagonizes death receptor signalling during bacterial 686 
gut infection. Nature 501, 247-251 (2013). 687 
19 Li, S. et al. Pathogen blocks host death receptor signalling by arginine GlcNAcylation of 688 
death domains. Nature 501, 242-246 (2013). 689 
20 Zhang, L. et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB 690 
activation. Nature 481, 204-208 (2012). 691 
 29
21 Charpentier, X. & Oswald, E. Identification of the secretion and translocation domain of the 692 
enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-693 
lactamase as a new fluorescence-based reporter. J Bacteriol 186, 5486-5495 (2004). 694 
22 Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-695 
kappaB signalling. Nature 430, 694-699 (2004). 696 
23 Newton, K. et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific 697 
antibodies. Cell 134, 668-678 (2008). 698 
24 Lin, Y., Devin, A., Rodriguez, Y. & Liu, Z. G. Cleavage of the death domain kinase RIP by 699 
caspase-8 prompts TNF-induced apoptosis. Genes Dev 13, 2514-2526 (1999). 700 
25 Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment 701 
search tool. J Mol Biol 215, 403-410 (1990). 702 
26 Kelley, L. A. & Sternberg, M. J. Protein structure prediction on the Web: a case study using 703 
the Phyre server. Nat Protoc 4, 363-371 (2009). 704 
27 Shao, F., Merritt, P. M., Bao, Z., Innes, R. W. & Dixon, J. E. A Yersinia effector and a 705 
Pseudomonas avirulence protein define a family of cysteine proteases functioning in 706 
bacterial pathogenesis. Cell 109, 575-588 (2002). 707 
28 Humphries, F., Yang, S., Wang, B. & Moynagh, P. N. RIP kinases: key decision makers in 708 
cell death and innate immunity. Cell Death Differ 22, 225-236 (2015). 709 
29 Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. 710 
Cell 131, 682-693 (2007). 711 
30 Wickham, M. E. et al. Bacterial genetic determinants of non-O157 STEC outbreaks and 712 
hemolytic-uremic syndrome after infection. J Infect Dis 194, 819-827 (2006). 713 
31 Conzen, S. D. & Cole, C. N. The three transforming regions of SV40 T antigen are required 714 
for immortalization of primary mouse embryo fibroblasts. Oncogene 11, 2295-2302 (1995). 715 
32 Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome 716 
through phagosomal destabilization. Nat Immunol 9, 847-856 (2008). 717 
33 Tanzer, M. C. et al. Evolutionary divergence of the necroptosis effector MLKL. Cell Death 718 
Differ 23, 1185-1197 (2016). 719 
34 Catanzariti, A. M., Soboleva, T. A., Jans, D. A., Board, P. G. & Baker, R. T. An efficient 720 
system for high-level expression and easy purification of authentic recombinant proteins. 721 
Protein Sci 13, 1331-1339 (2004). 722 
35 Galan, J. E., Ginocchio, C. & Costeas, P. Molecular and functional characterization of the 723 
Salmonella invasion gene invA: homology of InvA to members of a new protein family. J 724 
Bacteriol 174, 4338-4349 (1992). 725 
36 Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in 726 
Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97, 6640-6645. 727 
(2000). 728 
37 McKenzie, G. J. & Craig, N. L. Fast, easy and efficient: site-specific insertion of transgenes 729 
into enterobacterial chromosomes using Tn7 without need for selection of the insertion 730 
event. BMC Microbiol 6, 39 (2006). 731 
38 Huang, K. F., Chiou, S. H., Ko, T. P., Yuann, J. M. & Wang, A. H. The 1.35 A structure of 732 
cadmium-substituted TM-3, a snake-venom metalloproteinase from Taiwan habu: 733 
elucidation of a TNFalpha-converting enzyme-like active-site structure with a distorted 734 
octahedral geometry of cadmium. Acta Crystallogr D Biol Crystallogr 58, 1118-1128 735 
(2002). 736 
39 Gouet, P., Courcelle, E., Stuart, D. I. & Metoz, F. ESPript: analysis of multiple sequence 737 
alignments in PostScript. Bioinformatics 15, 305-308 (1999). 738 
40 Coppolino, M. G. et al. Requirement for N-ethylmaleimide-sensitive factor activity at 739 
different stages of bacterial invasion and phagocytosis. J Biol Chem 276, 4772-4780 (2001) 740 
 30
41 Edgar, R. C. MUSCLE: a multiple sequence alignment method with reduced time and space 741 
complexity. BMC Bioinformatics 5, 113 (2004). 742 
42 Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large 743 
phylogenies. Bioinformatics 30, 1312-1313 (2014). 744 
43 Huson, D. H. & Scornavacca, C. Dendroscope 3: an interactive tool for rooted phylogenetic 745 
trees and networks. Syst Biol 61, 1061-1067 (2012). 746 
44 Levine, M. M. et al. Escherichia coli strains that cause diarrhoea but do not produce heat- 747 
labile or heat-stable enterotoxins and are non-invasive. Lancet 1, 1119-1122 (1978). 748 
45 Newton, H. J. et al. The type III effectors NleE and NleB from enteropathogenic E. coli and 749 
OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog 6, 750 
e1000898 (2010). 751 
46 Garmendia, J. et al. TccP is an enterohaemorrhagic Escherichia coli O157:H7 type III 752 
effector protein that couples Tir to the actin-cytoskeleton. Cell Microbiol 6, 1167-1183 753 
(2004). 754 
47 Mundy, R. et al. Identification of a novel type IV pilus gene cluster required for 755 
gastrointestinal colonization of Citrobacter rodentium. Mol Microbiol 48, 795-809 (2003). 756 
48 Kelly, M. et al. Essential role of the type III secretion system effector NleB in colonization 757 
of mice by Citrobacter rodentium. Infect Immun 74, 2328-2337 (2006). 758 
49 Yamamoto, M. et al. A cluster of interferon-gamma-inducible p65 GTPases plays a critical 759 
role in host defense against Toxoplasma gondii. Immunity 37, 302-313 (2012) 760 
 761 
 762 
  763 
 31
Legend to the figures 764 
Figure 1. EspL is a T3SS cysteine protease that degrades RIPK1 and RIPK3. a, Schematic 765 
representation of EPEC E2348/69 genomic integrative element 6 (IE6) harbouring espL, nleB1, and 766 
nleE and immunoblot showing RIPK1 degradation in HT-29 cells infected with derivatives of 767 
EPEC E2348/69 as shown. Representative immunoblot from at least 3 independent experiments. 768 
Actin; loading control. b, Immunoblot showing RIPK1 degradation in HeLa cells uninfected or 769 
infected with EPEC E2348/69; untreated, or treated with either MG132 or z-VAD-FMK (z-VAD). 770 
Representative immunoblot from at least three independent experiments. Actin; loading control. c, 771 
Schematic representation of cysteine protease motif and secondary structure predicted by Phyre in 772 
YopT from Y. pestis KIM and EspL from EPEC E2348/69. d, Immunoblot showing levels of 773 
RIPK1, RIPK2 and RIPK3 in HT-29 cells infected with derivatives of EPEC E2348/69. 774 
Representative immunoblot from at least three independent experiments. Actin; loading control. 775 
 776 
Figure 2. Distribution of EspL in Gram negative pathogens and substrate specificity. a, 777 
Phylogeny of EspL homologues from a range of Gram negative pathogens which was midpoint 778 
rooted. Different genera are highlighted by background colour and the tips are coloured by species 779 
or pathotype. b, Coomassie Brilliant Blue stain of SDS PAGE gel showing in vitro cleavage of 780 
purified RHIM-containing regions of RIPK1, RIPK3, TRIF and ZBP1 (expressed as recombinant 781 
His6-ubiquitin-tagged proteins) by purified recombinant EspL. Representative gel from at least two 782 
independent experiments. Purified recombinant EspLC47S was used as a negative control. White 783 
arrows indicate cleavage products. Black arrows indicate EspL and the band corresponding to free 784 
His6-ubiquitin (His-Ub) Note, observed cleavage product derived from ZBP1/DAI was consistent 785 
with EspL cleavage in first RHIM of ZBP1/DAI. c, EspL cleavage site indicated by an arrow in the 786 
RHIM containing regions of RIPK1, RIPK3, TRIF and ZBP1/DAI. Alignment was performed using 787 
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Clustal Omega and ESPript3. Cleavage sites in RIPK3 and TRIF were determined experimentally 788 
by mass spectrometry and N-terminal sequencing.  789 
 790 
Figure 3. EspL inhibits TNF-induced necroptosis. a, Cell death visualised by propidium iodide 791 
(PI) staining in HT-29 cells infected with derivatives of EPEC and treated with TNF, compound A 792 
(Cp.A) and z-VAD-FMK (z-VAD). Hoechst; stain for nucleic acid. Scale bar, 20 μm. 793 
Representative images shown from at least three independent experiments. b, Quantification of PI 794 
staining from microscopic analysis in HT-29 cells infected with derivatives of EPEC E2348/69 and 795 
treated with TNF, Cp.A and z-VAD. Results are mean ± s.e.m. percentage of cells positive for PI 796 
staining from three independent experiments counting ~200 cells in triplicate. *P<0.0001 compared 797 
to EPEC E2348/69 infected cells, one-way ANOVA with Holm-Sidak multiple comparison. c, Blue 798 
native PAGE analysis of MLKL membrane translocation in HT-29 cells infected with derivatives of 799 
EPEC E2348/69 treated with TNF, Cp.A and z-VAD. Representative immunoblot from at least 800 
three independent experiments. GAPDH; cytosolic fraction loading control, VDAC; membrane 801 
fraction loading control. 802 
 803 
Figure 4. EspL activity inhibits TLR3/4-mediated signalling and contributes to in vivo 804 
persistence. a, Ifnβ expression in doxycycline-inducible iBMDMs stably expressing either Flag-805 
EspL or Flag-EspLC47S and treated with either LPS or Poly I:C for 3 h as indicated. Results are mean 806 
± s.e.m of at least three independent experiments performed in triplicate. Ifnβ expression relative to 807 
uninduced, unstimulated cells. *P<0.0005 compared to Flag-EspL induced with doxycycline and 808 
treated with LPS or poly I:C, unpaired, two-tailed t-test. b, MTT reduction in doxycycline-inducible 809 
iBMDMs stably expressing either Flag-EspL or Flag-EspLC47S and treated with either LPS/z-VAD 810 
or Poly I:C/z-VAD for 20 h. Results are mean ± s.e.m. of absorbance at 540 nm from three 811 
independent experiments performed in triplicate. *P< 0.05 compared to Flag-EspLC47S induced with 812 
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doxycycline and treated with LPS or poly I:C, unpaired, two-tailed t-test. c, Immunoblot showing 813 
degradation of endogenous RIPK1 by EspL from C. rodentium (Flag-CREspL) but not EspLC42S 814 
(Flag-CREspLC42S) expressed ectopically in HEK293T cells. Representative immunoblot from at 815 
least three independent experiments. d, Bacterial load in the faeces of mice 16 days after infection 816 
with derivatives of C. rodentium, including wild type C. rodentium ICC169 (CR), an espL deletion 817 
mutant (ΔespL) and ΔespL complemented with espL (EspL) or espLC42S (EspLC42S) by Tn7 818 
transposition. Each data point represents log10 c.f.u. per g faeces per individual animal (c.f.u., 819 
colony forming units). Mean ± s.e.m. are indicated. Data was combined from three independent 820 
experiments. P values from Mann–Whitney U-test. 821 
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